UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

UroGen Pharma Ltd.NASDAQ: URGN

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $7.63M rose 163.9% year over year, ahead of the -58.1% change in trailing-twelve-month accounts payables. Sequentially, it rose 371.3% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Accounts payables amounted to 0.3% of revenue in FY2025, down 11.8 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +163.9% holds above the trailing-twelve-month pace of -58.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.63M+371.3% QoQ
Last fiscal yearDec 2025
$286K-97.4% YoY
LTMMar 2026
$5.1M-58.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+163.9%——
1 year-97.4%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
286K USD
Year-over-year change
-97.4%
4-year CAGR
-38.5%

Accounts Payables vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's LTM Mar 2026 accounts payables of $5.1M is the largest of the 3 companies compared; the peer median is $1.32M.
  • Its year-over-year change of -58.1% is the 2nd highest of 3, against a peer median of +33.1%.
  • Accounts payables amounts to 3.6% of revenue for URGN, versus a peer median of 9.4%.
URGN Competitors Peer median
Accounts Payables for URGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
URGNUroGen Pharma Ltd.LTM Mar 2026$5.1M -58.1%+0.6%3.6%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$2.07M +152.7%——
CGONCG Oncology, Inc. Common stockLTM Sep 2026$579K -86.5%+350.3%9.4%
Peer median (excluding URGN) $1.32M+33.1%+350.3%9.4%

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(110.82M)(109.78M)(102.24M)(126.87M)(153.49M)
Depreciation & Amortization1.77M1.82M1.71M1.19M2.41M
Deferred Income Tax15.32M0000
Stock-Based Compensation23.11M10.58M9.34M13.11M11.96M
Change in Working Capital(13.11M)(6.31M)3.34M4.93M(27.91M)
Accounts Receivables(4.67M)(987K)(2.74M)(4.86M)(12.78M)
Inventory(2.87M)(362K)(1.35M)(3.55M)(7.24M)
Accounts Payables2M281K4.16M10.89M286K
Other Working Capital(7.57M)(5.24M)3.27M2.45M(8.18M)
Other Non-Cash Items(1.18M)16.13M11.48M10.88M4.59M
Operating Cash Flow(84.89M)(87.56M)(76.38M)(96.77M)(162.44M)
Capital Expenditures(752K)(254K)(194K)(295K)(289K)
Acquisitions (Net)(4.82M)(1.31M)000
Purchases of Investments(51.9M)(63.01M)(49.83M)(128.02M)(77.4M)
Sales of Investments56.72M64.32M49.07M107.71M139.25M
Other Investing Activities4.82M1.31M000
Investing Cash Flow4.07M1.06M(953K)(20.61M)61.56M
Debt Repayment095.78M024.49M(1.86M)
Common Stock Issued(83K)1.35M67.36M151.17M41.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities72.4M(160K)49.57M18.96M0
Financing Cash Flow72.32M97.13M116.93M194.62M39.92M
Effect of Forex Changes00000
Net Change in Cash(8.5M)10.64M39.6M77.24M(60.97M)
Free Cash Flow(85.64M)(87.81M)(76.57M)(97.06M)(162.73M)

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.